Pharmacokinetic and pharmacodynamic variability as possible causes for different drug responses in migraine. A comment

Cephalalgia

Volumn 27, Issue 10, 2007, Pages 1091-1093

  Tfelt Hansen, P ^a   Edvinsson, L ^b  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Migraine; Pharmacodynamics; Pharmacokinetics; Variability

Indexed keywords

ANTIMIGRAINE AGENT; ELETRIPTAN; NARATRIPTAN; RIZATRIPTAN; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SUMATRIPTAN; ZOLMITRIPTAN;

CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG RESPONSE; HEADACHE; HUMAN; MIGRAINE; REVIEW;

BIOLOGICAL AVAILABILITY; CEREBRAL ARTERIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MIGRAINE DISORDERS; SEROTONIN AGONISTS;

EID: 34748846390     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2007.01372.x     Document Type: Review

References (14)

1. Saxena PR, Tfelt-Hansen P. Triptans, 5HT1B/1D agonists in the acute treatment of migraine. In : Olesen J, Goadsby PJ, Ramadan MN, Tfelt-Hansen P, Welch KMA, editors. The headaches, 3rd edn. Philadelphia : Lippincott Williams & Wilkins 2006 : 469 503.
2. Volans GN. Absorption of effervescent aspirin during migraine. BMJ 1974 4 : 265 9.
3. Volans GN. The effect of metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol 1975 2 : 57 63.
4. Thomsen LL, Dixon R, Lassen LH, Giboens M, Langemark M, Bendtsen L et al. 311C90 (zolmitritan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia 1996 16 : 270 5.
5. Tfelt-Hansen P, Young WB, Silberstein SD. Antiemetics, prokinetics, neuroleptic and miscellaneous drugs in the acute treatment of migraine. In : Olesen J, Goadsby PJ, Ramadan MN, Tfelt-Hansen P, Welch KMA, editors. The headaches, 3rd edn. Philadelphia : Lippincott Williams & Wilkins 2006 : 505 13.
6. Rowland M, Sheiner LB, Steimer J-L, eds. Variability in drug therapy. Description, estimation, and control. New York : Ravens Press 1985.
7. Seaber E, On N, Dixon RM, Gibbens M, Leavens WJ, Liptrop J et al. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). Br J Clin Pharmacol 1997 43 : 579 87.
8. Lacey LF, Hussey EK, Fowler PA. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 1995 47 : 543 8.
9. Skärby T, Tfelt-Hansen P, Gjerris F, Edvinsson L, Olesen J. Characterization of the 5-hydroxy-tryptamine receptor in human temporal arteries; comparison between migraine sufferers and non-sufferers. Ann Neurol 1982 12 : 272 7.
10. Edvinsson L, Skärby T, Tfelt-Hansen P, Gjerris F, Olesen J. Presence of alpha-adrenoreceptors in human temporal arteries. Comparison between migraine patients and controls. Cephalalgia 1983 3 : 219 24.
11. Tfelt-Hansen P, Jansen-Olesen I, Mortensen A, Edvinsson L. Variability of vascular receptors on the human cerebral arteries as determined in vitro. In : Olesen J, Edvinsson L, editors. 7th International Headache Research Seminar. Messenger molecules in headache pathogenesis: monoamines, purines, neuropeptides and nitric oxide. New York : Lippincot-Raven 1997 : 173 6.
12. Tfelt-Hansen P, Edvinsson L. Variability of the vascular alpha-adrenoceptor on human omental vessels. An in vitro study. In : Olesen J, Edvinsson L, editors. 7th International Headache Research Seminar. Messenger molecules in headache pathogenesis: monoamines, purines, neuropeptides and nitric oxide. New York : Lippincot-Raven 1997 : 177 80.
13. Edvinsson L, Uddman E, Wackenfors A, Davenport A, Longmore J, Malmsjö M. Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries: relationship to clinical effect. Cli Sci 2005 109 : 335 42.
14. Dahlöf C, Hogenhuis L, Olesen J, Petit H, Ribbat J, Schoenen J et al. Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study. Eur J Neurol 1998 5 : 469 77.